Associate Professor
What I love most about epidemiology is that we use data to make an impact in the lives of people who need it the most. In my work as a cancer epidemiologist, I focus on understanding why cancer health disparities exist so that we can provide data-informed solutions to reduce the unequal burden.
I also work to understand the larger context that creates racial disparities in cancer occurrence and outcomes, which is a unique part of public health. Our goal is to create healthier environments so that people can live their best lives.
Contact
1841 Neil Ave.
304 Cunz Hall
Columbus, OH, 43210
Email: felix.20@osu.edu
Dr. Felix is a cancer epidemiologist with strong interests in the molecular epidemiology of gynecologic malignancies. Specifically, Dr. Felix’s research activities include refining risk factors associations for heterogeneous endometrial cancer subtypes, investigating the molecular mechanisms that underlie these relationships, and identifying modifiable factors that can improve prognosis among endometrial cancer patients. Her work has specifically focused on women diagnosed with clinically aggressive endometrial tumors, which represent a diverse and understudied group of tumors, characterized by racial disparities.
Cancer epidemiology; women’s health; racial disparities; molecular epidemiology; screening and early detection
- Postdoctoral Fellowship in Cancer Prevention, National Cancer Institute, 2011-2015
- PhD, Epidemiology, University of Pittsburgh, 2007-2011
- MPH, Epidemiology, University of Michigan, 2005-2007
- BA, Public Health, Johns Hopkins University, 2001-2005
Luo J, Chlebowski RT, Hendryx M, Rohan T, Wactawski-Wende J, Thomson CA, Felix AS, Chen C, Barrington W, Coday M, Stefanick M, LeBlanc E, Margolis KL. Intentional Weight Loss and Endometrial Cancer Risk. J Clin Oncol. 2017 Apr 10;35(11):1189-1193. doi: 10.1200/JCO.2016.70.5822. Epub 2017 Feb 6.
Brasky TM, Felix AS, Cohn DE, McMeekin DS, Mutch DG, Creasman WT, Thaker PH, Walker JL, Moore RG, Lele SB, Guntupalli SR, Downs LS, Nagel CI, Boggess JF, Pearl ML, Ioffe OB, Park KJ, Ali S, Brinton LA. Nonsteroidal Anti-inflammatory Drugs and Endometrial Carcinoma Mortality and Recurrence. J Natl Cancer Inst. 2017 Mar 1;109(3):1-10. doi: 10.1093/jnci/djw251.
Suarez AA, Felix AS, Cohn DE. Bokhman Redux: Endometrial cancer "types" in the 21st century. Gynecol Oncol. 2017 Feb;144(2):243-249. doi: 10.1016/j.ygyno.2016.12.010. Epub 2016 Dec 16.
Felix AS, Bower JK, Pfeiffer RM, Raman SV, Cohn DE, Sherman ME. High cardiovascular disease mortality after endometrial cancer diagnosis: Results from the Surveillance, Epidemiology, and End Results (SEER) Database. Int J Cancer. 2017 Feb 1;140(3):555-564. doi: 10.1002/ijc.30470. Epub 2016 Nov 14.
Felix AS, Yang HP, Bell DW, Sherman ME. Epidemiology of Endometrial Carcinoma: Etiologic Importance of Hormonal and Metabolic Influences. Adv Exp Med Biol. 2017;943:3-46.
Felix AS, Lenz P, Pfeiffer RM, Hewitt SM, Morris J, Patel DA, Geller B, Vacek PM, Weaver DL, Chicoine RE, Shepherd J, Mahmoudzadeh AP, Wang J, Fan B, Malkov S, Herschorn SD, Johnson JM, Cora RL, Brinton LA, Sherman ME, Gierach GL. Relationships between mammographic density, tissue microvessel density, and breast biopsy diagnosis. Breast Cancer Res. 2016 Aug 23;18(1):88. doi: 10.1186/s13058-016-0746-9.
Brinton LA, Trabert B, Anderson GL, Falk RT, Felix AS, Fuhrman BJ, Gass ML, Kuller LH, Pfeiffer RM, Rohan TE, Strickler HD, Xu X, Wentzensen N. Serum Estrogens and Estrogen Metabolites and Endometrial Cancer Risk among Postmenopausal Women. Cancer Epidemiol Biomarkers Prev. 2016 Jul;25(7):1081-9. doi: 10.1158/1055-9965.EPI-16-0225. Epub 2016 Apr 12.